BioCryst Pharmaceuticals
BCRX
BCRX
165 hedge funds and large institutions have $635M invested in BioCryst Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 55 increasing their positions, 37 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
49% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 37
23% more funds holding
Funds holding: 134 → 165 (+31)
4.01% less ownership
Funds ownership: 79.51% → 75.5% (-4%)
Holders
165
Holding in Top 10
3
Calls
$11.2M
Puts
$3.31M
Top Buyers
| 1 | +$46.9M | |
| 2 | +$13.4M | |
| 3 | +$11.3M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.1M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$9.53M |
Top Sellers
| 1 | -$23.5M | |
| 2 | -$15M | |
| 3 | -$12.8M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.2M |